A double-blind, 4-period crossover, abuse liability study assessing clinical abuse of Opana extended release and oxymorphone HCl powder in healthy non-dependent opioid users.
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Oxymorphone (Primary) ; Oxymorphone (Primary)
- Indications Pain
- Focus Pharmacodynamics
- 09 Jun 2016 New trial record
- 14 May 2016 Primary endpoint has bee met (Median difference for Emax) as per an abstract presented at the 35th Annual Scientific Meeting of the American Pain Society
- 14 May 2016 Results presented at the 35th Annual Scientific Meeting of the American Pain Society